Prosion

Executive Summary

Prosion Therapeutics is a German drug development company, founded in 2001 and headquartered in Hamburg, dedicated to addressing highly unmet medical needs in oncology. The company leverages its proprietary advanced antibody platform to target previously undruggable proteins, aiming to develop novel cancer treatments. With over two decades of focused research, Prosion has built a robust expertise in antibody engineering, positioning itself to tackle challenging targets that have eluded conventional therapies. Its mission centers on translating innovative biology into effective therapeutics, potentially offering new options for patients with limited treatment alternatives. Despite its long history, Prosion remains a private entity with limited public disclosures, suggesting a strategic emphasis on research and development prior to larger clinical or commercial milestones. Prosion's approach targets the 'undruggable' proteome, a significant area of unmet need in oncology. The company's antibody platform enables specific binding to challenging intracellular or conformational epitopes, expanding the druggable space. While specific pipeline candidates are not publicly detailed, the company's long-standing focus and expertise suggest progress toward lead optimization and preclinical validation. The potential impact of successfully targeting undruggable proteins could be transformative, particularly in cancers with high resistance rates. However, the lack of disclosed clinical data or partnerships places Prosion in a high-risk, high-reward category typical of early-stage biotech firms.

Upcoming Catalysts (preview)

• Q4 2026Lead IND-enabling studies completion40% success
• Q2 2027Preclinical proof-of-concept data publication50% success
• Q1 2027Strategic partnership or licensing deal30% success